Digestive Diseases and Sciences

, Volume 54, Issue 5, pp 1120–1127 | Cite as

Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C

  • Qing-Hua Meng
  • Zhong-Hui Duan
  • Zun-Hui Lin
  • Hong-Wei Yu
  • Juan Li
  • Ya Liu
Original Article


Adiponectin is well recognized as plasma physiologically active polypeptide hormone exclusively derived from human and animal mature adipocytes, with vigorous property in antidiabetic, antiobesity, antiatherogenic, and anti-inflammatory processes. In this study, we investigated the correlation between serum adiponectin level and clinical and pathological parameters in patients with chronic hepatitis C (CHC). The study included 127 patients with CHC and 42 healthy volunteers as controls whose laboratory parameters and serum adiponectin and tumor necrosis factor-α (TNF-α) were assessed using enzyme-linked immunosorbent assay (ELISA). We demonstrated that a lower serum adiponectin level was associated with male gender, higher γ-glutamyltransferase (γ-GGT), higher albumin, higher TNF-α, and steatosis grade. The higher level of serum adiponectin in patients with genotype 2a was demonstrated when compared with that in the patients with genotype 1b. Furthermore, of great interest, results suggested that the significant differences regarding viral genotype seemed to occur only in male patients with CHC but not in female patients. In conclusion, serum adiponectin was associated with gender, genotype, liver steatosis, and TNF-α in a Chinese population with CHC.


Hepatitis C Chronic Adiponectin Genotype Steatosis Gender 



This work was supported by funding from the Beijing Science and Technology Committee (2004054) to Qing-Hua Meng.


  1. 1.
    Semple RK, Halberg NH, Burling K, et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes. 2007;56:1712–1717. doi: 10.2337/db06-1665.PubMedCrossRefGoogle Scholar
  2. 2.
    Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension. 2007;49:1455–1461. doi: 10.1161/HYPERTENSIONAHA.107.086835.PubMedCrossRefGoogle Scholar
  3. 3.
    Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54. doi: 10.1002/hep.20280.PubMedCrossRefGoogle Scholar
  4. 4.
    Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197–1211. doi: 10.1038/oby.2004.151.PubMedCrossRefGoogle Scholar
  5. 5.
    Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR study. Stroke. 2005;36:2577–2582. doi: 10.1161/01.STR.0000190834.00284.fd.PubMedCrossRefGoogle Scholar
  6. 6.
    Semple RK, Soos MA, Luan J, et al. Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab. 2006;91:3219–3223. doi: 10.1210/jc.2006-0166.PubMedCrossRefGoogle Scholar
  7. 7.
    Ohashi K, Kihara S, Ouchi N, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47:1108–1116. doi: 10.1161/01.HYP.0000222368.43759.a1.PubMedCrossRefGoogle Scholar
  8. 8.
    Otsuka F, Sugiyama S, Kojima S, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006;48:1155–1162. doi: 10.1016/j.jacc.2006.05.054.PubMedCrossRefGoogle Scholar
  9. 9.
    Raitakari M, Ilvonen T, Ahotupa M, et al. Weight reduction with very-low-caloric diet and endothelial function in overweight adults: role of plasma glucose. Arterioscler Thromb Vasc Biol. 2004;24:124–128. doi: 10.1161/01.ATV.0000109749.11042.7c.PubMedCrossRefGoogle Scholar
  10. 10.
    Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K. Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia. 2005;48:1066–1074. doi: 10.1007/s00125-005-1766-7.PubMedCrossRefGoogle Scholar
  11. 11.
    Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48:1369–1377. doi: 10.1016/j.jacc.2006.06.053.PubMedCrossRefGoogle Scholar
  12. 12.
    Siagris D, Vafiadis G, Michalaki M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat. 2007;14:577–583. doi: 10.1111/j.1365-2893.2007.00850.x.PubMedCrossRefGoogle Scholar
  13. 13.
    Yoda-Murakami M, Taniguchi M, Takahashi K, et al. Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun. 2001;285:372–377. doi: 10.1006/bbrc.2001.5134.PubMedCrossRefGoogle Scholar
  14. 14.
    Kamada Y, Tamura S, Kiso S, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003;125:1796–1807. doi: 10.1053/j.gastro.2003.08.029.PubMedCrossRefGoogle Scholar
  15. 15.
    Lu JY, Chuang LM, Yang WS, et al. Adiponectin levels among patients with chronic hepatitis B and C infections and in response to IFN-alpha therapy. Liver Int. 2005;25:752–759. doi: 10.1111/j.1478-3231.2005.1007.x.PubMedCrossRefGoogle Scholar
  16. 16.
    Jonsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol. 2005;43:929–936. doi: 10.1016/j.jhep.2005.05.030.PubMedCrossRefGoogle Scholar
  17. 17.
    Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocrinol Metab. 2005;90:2240–2243. doi: 10.1210/jc.2004-1266.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117–121. doi: 10.1136/gut.2003.037010.PubMedCrossRefGoogle Scholar
  19. 19.
    Wang AY, Hickman IJ, Richards AA, Whitehead JP, Prins JB, Macdonald GA. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol. 2005;100:2717–2723. doi: 10.1111/j.1572-0241.2005.00311.x.PubMedCrossRefGoogle Scholar
  20. 20.
    Hyogo H, Yamagishi S, Iwamoto K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007;22:1112–1119. doi: 10.1111/j.1440-1746.2007.04943.x.PubMedCrossRefGoogle Scholar
  21. 21.
    Durante-Mangoni E, Zampino R, Marrone A, et al. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther. 2006;24:1349–1357. doi: 10.1111/j.1365-2036.2006.03114.x.PubMedCrossRefGoogle Scholar
  22. 22.
    Kamada Y, Matsumoto H, Tamura S, et al. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol. 2007;47:556–564. doi: 10.1016/j.jhep.2007.03.020.PubMedCrossRefGoogle Scholar
  23. 23.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46. doi: 10.1002/hep.1840360706.PubMedCrossRefGoogle Scholar
  24. 24.
    Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–787. doi: 10.1002/hep.21078.PubMedCrossRefGoogle Scholar
  25. 25.
    Cua IH, Hui JM, Bandara P, et al. Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology. 2007;46:66–73. doi: 10.1002/hep.21703.PubMedCrossRefGoogle Scholar
  26. 26.
    Adachi M, Brenner DA. Clinical syndromes of alcoholic liver disease. Dig Dis Sci. 2005;23:255–263. doi: 10.1159/000090173.CrossRefGoogle Scholar
  27. 27.
    Hui CK, Zhang HY, Lee NP, et al. Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B. J Hepatol. 2007;47:191–202. doi: 10.1016/j.jhep.2007.02.023.PubMedCrossRefGoogle Scholar
  28. 28.
    Tacke F, Wustefeld T, Horn R, et al. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J Hepatol. 2005;42:666–673. doi: 10.1016/j.jhep.2004.12.024.PubMedCrossRefGoogle Scholar
  29. 29.
    Noble JH Jr. Declaration of Helsinki. Dead. BMJ. 2007;335:736. doi: 10.1136/bmj.39360.415833.BE.PubMedCrossRefGoogle Scholar
  30. 30.
    Buti M, Sanchez-Avila F, Lurie Y, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930–936. doi: 10.1053/jhep.2002.32150.PubMedCrossRefGoogle Scholar
  31. 31.
    Jones DE, Donaldson PT. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin Liver Dis. 2003;7:841–864. doi: 10.1016/S1089-3261(03)00095-3.PubMedCrossRefGoogle Scholar
  32. 32.
    McCullough AJ, Bugianesi E, Marchesini G, Kalhan SC. Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology. 1998;115:947–953. doi: 10.1016/S0016-5085(98)70267-7.PubMedCrossRefGoogle Scholar
  33. 33.
    Liu CJ, Chen PJ, Jeng YM, et al. Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. J Hepatol. 2005;43:235–242. doi: 10.1016/j.jhep.2005.02.044.PubMedCrossRefGoogle Scholar
  34. 34.
    Morris AM, Sennello JA, Fayad RA, Eckel RH, Dinarello CA, Fantuzzi G. T cell-mediated hepatic inflammation modulates adiponectin levels in mice: role of tumor necrosis factor alpha. Metabolism. 2006;55:555–559. doi: 10.1016/j.metabol.2005.11.008.PubMedCrossRefGoogle Scholar
  35. 35.
    Sato S, Furuta K, Mishiro T, et al. Serum adiponectin concentration in patients with hepatitis C virus. J Clin Gastroenterol. 2005;39:744–745. doi: 10.1097/01.mcg.0000173933.69524.64.PubMedCrossRefGoogle Scholar
  36. 36.
    Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94:e27–e31. doi: 10.1161/01.RES.0000119921.86460.37.PubMedCrossRefGoogle Scholar
  37. 37.
    Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–18080. doi: 10.1074/jbc.M414231200.PubMedCrossRefGoogle Scholar
  38. 38.
    Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis. Chang Gung Med J. 2004;27:855–868.PubMedGoogle Scholar
  39. 39.
    Kara B, Gunesacar R, Doran F, Kara IO, Akkiz H. Correlation of serum adiponectin levels and hepatic steatosis in hepatitis C virus genotype 1 infection. Adv Ther. 2007;24:972–982. doi: 10.1007/BF02877701.PubMedCrossRefGoogle Scholar
  40. 40.
    Yamada G, Iino S, Okuno T, et al. Virological response in patients with hepatitis C virus genotype 1b and a high viral load : impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig. 2008;28:9–16. doi: 10.2165/00044011-200828010-00002.PubMedCrossRefGoogle Scholar
  41. 41.
    Dal Pero F, Tang KH, Gerotto M, et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis. 2007;196:998–1005. doi: 10.1086/521306.PubMedCrossRefGoogle Scholar
  42. 42.
    Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40 KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44:275–282. doi: 10.1016/j.jhep.2005.09.015.PubMedCrossRefGoogle Scholar
  43. 43.
    Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat. 2006;13:371–376. doi: 10.1111/j.1365-2893.2005.00697.x.PubMedCrossRefGoogle Scholar
  44. 44.
    Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol. 2006;101:2629–2640.PubMedGoogle Scholar
  45. 45.
    Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167–1174. doi: 10.1016/j.jhep.2006.02.011.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Qing-Hua Meng
    • 1
    • 2
  • Zhong-Hui Duan
    • 2
  • Zun-Hui Lin
    • 3
  • Hong-Wei Yu
    • 2
  • Juan Li
    • 2
  • Ya Liu
    • 1
  1. 1.Public Health InstituteJilin UniversityChangchunChina
  2. 2.Beijing YouAn HospitalCapital Medical UniversityBeijingChina
  3. 3.Hepatitis Institute of Beijing Public Health BureauBeijingChina

Personalised recommendations